| Year |
Citation |
Score |
| 2022 |
Wang H, Khattar V, Hensel JA, Ashton R, Lu Y, Sorace AG, Wang Y, Deshane JS, Mieher JL, Deivanayagam C, Ponnazhagan S. Systemic checkpoint blockade by PD-L1 single-chain antibody confers potent anti-tumor immunity and long-term survival. Molecular Cancer Therapeutics. PMID 36031328 DOI: 10.1158/1535-7163.MCT-22-0010 |
0.727 |
|
| 2020 |
Wang H, Ashton R, Hensel JA, Lee JH, Khattar V, Wang Y, Deshane JS, Ponnazhagan S. RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. Molecular Cancer Therapeutics. PMID 33199500 DOI: 10.1158/1535-7163.MCT-20-0378 |
0.783 |
|
| 2020 |
Wang Y, Goliwas KF, Severino PE, Hough KP, Van Vessem D, Wang H, Tousif S, Koomullil RP, Frost AR, Ponnazhagan S, Berry JL, Deshane JS. Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 32572176 DOI: 10.1038/S41374-020-0452-1 |
0.443 |
|
| 2020 |
Kwon HJ, Qing K, Ponnazhagan S, Wang XS, Markusic DM, Gupte S, Boye S, Srivastava A. AAV D-sequence-mediated suppression of expression of a human major histocompatibility class II gene: Implications in the development of AAV vectors for modulating humoral immune response. Human Gene Therapy. PMID 32220217 DOI: 10.1089/Hum.2020.018 |
0.309 |
|
| 2020 |
Cha HR, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Research. PMID 32066566 DOI: 10.1158/0008-5472.Can-19-2948 |
0.455 |
|
| 2020 |
Xu X, Zhang C, Trotter TN, Gowda PS, Lu Y, Ponnazhagan S, Javed A, Li J, Yang Y. Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites. Cancer Research. PMID 31911552 DOI: 10.1158/0008-5472.Can-19-0284 |
0.428 |
|
| 2019 |
Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity. Molecular Therapy Oncolytics. 12: 41-48. PMID 30666318 DOI: 10.1016/J.Omto.2018.12.004 |
0.77 |
|
| 2018 |
Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 30353130 DOI: 10.1038/S41374-018-0137-1 |
0.738 |
|
| 2018 |
Urbanska AM, Ponnazhagan S, Mozafari M. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. Cancer Research. PMID 29959150 DOI: 10.1158/0008-5472.Can-18-0206 |
0.346 |
|
| 2018 |
Wang Y, Schafer CC, Hough KP, Tousif S, Duncan SR, Kearney JF, Ponnazhagan S, Hsu HC, Deshane JS. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5. Journal of Immunology (Baltimore, Md. : 1950). PMID 29752311 DOI: 10.4049/Jimmunol.1701069 |
0.409 |
|
| 2018 |
Kumar S, Stoke J, Malik S, Singh UP, Ponnazhagan S, Manne U, Mishra MK. Abstract 4690: FoxP3+T cells program/re-program the prostatic tumor microenvironment Immunology. 78: 4690-4690. DOI: 10.1158/1538-7445.Am2018-4690 |
0.428 |
|
| 2017 |
Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD, Ponnazhagan S. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Advances. 1: 2375-2385. PMID 29296887 DOI: 10.1182/Bloodadvances.2017007310 |
0.794 |
|
| 2017 |
Chanda D, Hensel JA, Higgs JT, Grover R, Kaza N, Ponnazhagan S. Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus. Genes. 8. PMID 28926997 DOI: 10.3390/Genes8090232 |
0.734 |
|
| 2017 |
Moore-Smith LD, Isayeva T, Lee JH, Frost A, Ponnazhagan S. Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment. Scientific Reports. 7: 8678. PMID 28819116 DOI: 10.1038/S41598-017-09062-Y |
0.375 |
|
| 2017 |
McConnell M, Feng S, Chen W, Zhu G, Shen D, Ponnazhagan S, Deng L, Li YP. Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. Oncotarget. PMID 28504970 DOI: 10.18632/Oncotarget.17544 |
0.469 |
|
| 2017 |
Hensel JA, Khattar V, Ashton R, Lee C, Siegal GP, Ponnazhagan S. Location of tumor affects local and distant immune cell type and number. Immunity, Inflammation and Disease. 5: 85-94. PMID 28250928 DOI: 10.1002/Iid3.144 |
0.767 |
|
| 2017 |
Kumar S, Eroglu E, Stokes JA, Scissum-Gunn K, Saldanha SN, Singh UP, Manne U, Ponnazhagan S, Mishra MK. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. Oncotarget. PMID 28157696 DOI: 10.18632/Oncotarget.14947 |
0.437 |
|
| 2017 |
Lee JH, Kang M, Wang H, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28069826 DOI: 10.1096/Fj.201601178R |
0.4 |
|
| 2017 |
Kumar S, Stokes J, Singh U, Gunn KS, Manne U, Ponnazhagan S, Mishra MK. Abstract 2955: Gr1-MDSCs and Tregs modulate the prostate cancer progression Cancer Research. 77: 2955-2955. DOI: 10.1158/1538-7445.Am2017-2955 |
0.362 |
|
| 2017 |
Lee JH, Kang M, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S. Abstract 1585: Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress Endocrinology. 77: 1585-1585. DOI: 10.1158/1538-7445.Am2017-1585 |
0.353 |
|
| 2016 |
Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S, Deshane JS. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget. PMID 27705910 DOI: 10.18632/Oncotarget.12249 |
0.446 |
|
| 2016 |
Levy S, Feduska JM, Sawant A, Gilbert S, Hensel JA, Ponnazhagan S. Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade. Bone. PMID 27664567 DOI: 10.1016/J.Bone.2016.09.018 |
0.734 |
|
| 2016 |
Cha HR, Lee JH, Hensel JA, Sawant AB, Davis BH, Lee CM, Deshane JS, Ponnazhagan S. Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages. The Prostate. PMID 26856684 DOI: 10.1002/Pros.23155 |
0.778 |
|
| 2016 |
Kumar S, Stokes J, Gunn KS, Ponnazhagan S, Manne U, Mishra MK. Abstract 4328: Resveratrol inhibits NO-mediated oxidative stress in murine prostate cancer cells Cancer Research. 76: 4328-4328. DOI: 10.1158/1538-7445.Am2016-4328 |
0.423 |
|
| 2016 |
Feduska J, Lee C, Ponnazhagan S. Abstract 2539: Cell cycle regulation influences the phenotype of breast and prostate cancer stem cellsin vitro Cancer Research. 76: 2539-2539. DOI: 10.1158/1538-7445.Am2016-2539 |
0.486 |
|
| 2016 |
Kumar S, Stokes J, Gunn KS, Singh U, Ponnazhagan S, Mishra MK. Abstract 1457: Regulatory T cells and its impact on prostate cancer development and clearance Immunology. 76: 1457-1457. DOI: 10.1158/1538-7445.Am2016-1457 |
0.382 |
|
| 2016 |
Lee JH, Kang M, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S. Abstract 1011: Endostatin regulates androgen receptor-mediated metabolic and oxido-reductive pathways in prostate cancer cells Cancer Research. 76: 1011-1011. DOI: 10.1158/1538-7445.Am2016-1011 |
0.422 |
|
| 2015 |
Yu H, Liu Y, McFarland BC, Deshane JS, Hurst DR, Ponnazhagan S, Benveniste EN, Qin H. SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. Cancer Immunology Research. 3: 727-40. PMID 25649351 DOI: 10.1158/2326-6066.Cir-15-0004 |
0.429 |
|
| 2015 |
Higgs JT, Jarboe JS, Lee JH, Chanda D, Lee CM, Deivanayagam C, Ponnazhagan S. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. Molecular Cancer Research : McR. 13: 819-27. PMID 25636966 DOI: 10.1158/1541-7786.Mcr-14-0492 |
0.787 |
|
| 2015 |
Lee JH, Isayeva T, Larson MR, Sawant A, Cha HR, Chanda D, Chesnokov IN, Ponnazhagan S. Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 1392-7. PMID 25605930 DOI: 10.1073/Pnas.1417660112 |
0.382 |
|
| 2015 |
Lee JH, Mobley JA, Ponnazhagan S. Abstract 5050: Proteome-based combined treatment strategies synergizing antagonism of androgen receptor function in prostate cancer Cancer Research. 75: 5050-5050. DOI: 10.1158/1538-7445.Am2015-5050 |
0.449 |
|
| 2015 |
Cha H, Hensel J, Ponnazhagan S. Abstract 434: Prostate cancer cell-derived cathelicidin-related antimicrobial peptide regulates MCP-1 and CXCL1/2 through autocrine signaling Cancer Research. 75: 434-434. DOI: 10.1158/1538-7445.Am2015-434 |
0.793 |
|
| 2014 |
Sawant A, Schafer CC, Ponnazhagan S, Deshane JS. The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer. Oncoimmunology. 3: e27401. PMID 24711958 DOI: 10.4161/Onci.27401 |
0.363 |
|
| 2014 |
Chanda D, Lee JH, Sawant A, Hensel JA, Isayeva T, Reilly SD, Siegal GP, Smith C, Grizzle W, Singh R, Ponnazhagan S. Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancer. Plos One. 9: e89940. PMID 24587138 DOI: 10.1371/Journal.Pone.0089940 |
0.793 |
|
| 2014 |
Schafer CC, Wang Y, Sawant A, Jin TH, Ponnazhagan S, Grant SC, Deshane JS. Abstract 634: Combination chemotherapy significantly reduces indoleamine 2,3-dioxygenase activity in NSCLC patients Cancer Research. 74: 634-634. DOI: 10.1158/1538-7445.Am2014-634 |
0.354 |
|
| 2014 |
Lee JH, Isayeva T, Larson M, Chanda D, Chesnokov I, Ponnazhagan S. Abstract 612: Endostatin is a novel inhibitor of androgen receptor function in prostate cancer Cancer Research. 74: 612-612. DOI: 10.1158/1538-7445.Am2014-612 |
0.435 |
|
| 2014 |
Sawant A, Lee C, Schafer C, Deshane J, Ponnazhagan S. Abstract 2794: CD8+ natural regulatory T cells as antitumor immune effectors in carcinomas of breast and lung Cancer Research. 74: 2794-2794. DOI: 10.1158/1538-7445.Am2014-2794 |
0.413 |
|
| 2014 |
Cha H, Sawant A, Hensel J, Lee C, Ponnazhagan S. Abstract 162: Immunomodulatory role of CRAMP (cathelicidin-related antimicrobial peptide) in prostate cancer Cancer Research. 74: 162-162. DOI: 10.1158/1538-7445.Am2014-162 |
0.799 |
|
| 2013 |
Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Research. 73: 6609-20. PMID 24085788 DOI: 10.1158/0008-5472.Can-13-0987 |
0.419 |
|
| 2013 |
Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Research. 73: 4606-10. PMID 23887974 DOI: 10.1158/0008-5472.Can-13-0305 |
0.5 |
|
| 2013 |
Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. Oncoimmunology. 2: e24064. PMID 23762794 DOI: 10.4161/Onci.24064 |
0.388 |
|
| 2013 |
Sawant A, Ponnazhagan S. Role of plasmacytoid dendritic cells in breast cancer bone dissemination. Oncoimmunology. 2: e22983. PMID 23526329 DOI: 10.4161/Onci.22983 |
0.422 |
|
| 2013 |
Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, Ponnazhagan S. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research. 73: 672-82. PMID 23243021 DOI: 10.1158/0008-5472.Can-12-2202 |
0.465 |
|
| 2013 |
Culpepper BK, Bonvallet PP, Reddy MS, Ponnazhagan S, Bellis SL. Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone. Biomaterials. 34: 1506-13. PMID 23182349 DOI: 10.1016/J.Biomaterials.2012.10.046 |
0.315 |
|
| 2013 |
Cha H, Sawant A, Lee C, Hensel J, Tsuladze G, Ponnazhagan S. Abstract B86: Immunomodulatory effects of LL-37/CRAMP in prostate cancer progression. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B86 |
0.494 |
|
| 2013 |
Lee CM, Sawant A, Cha H, Ponnazhagan S. Abstract 250: Growth characteristics of breast cancer stem cellsin vitroandin vivo. Cancer Research. 73: 250-250. DOI: 10.1158/1538-7445.Am2013-250 |
0.462 |
|
| 2012 |
Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A, Ponnazhagan S. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 4258-65. PMID 23018462 DOI: 10.4049/Jimmunol.1101855 |
0.789 |
|
| 2012 |
Sawant A, Chanda D, Isayeva T, Tsuladze G, Garvey WT, Ponnazhagan S. Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity. The Journal of Biological Chemistry. 287: 12241-9. PMID 22351751 DOI: 10.1074/Jbc.M111.293613 |
0.334 |
|
| 2012 |
Kumar S, Ponnazhagan S. Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect Bone. 50: 1012-1018. PMID 22342795 DOI: 10.1016/J.Bone.2012.01.027 |
0.391 |
|
| 2012 |
Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunology, Immunotherapy : Cii. 61: 1441-50. PMID 22310929 DOI: 10.1007/S00262-012-1204-X |
0.353 |
|
| 2012 |
Chanda D, Sawant A, Hensel JA, Isayeva T, Reilly SD, Siegal GP, Smith C, Ponnazhagan S. Abstract B52: Loss of anterior gradient protein in high-grade prostate cancer is associated with loss of tumor cell adhesion and epithelial cell polarity Cancer Research. 72: B52-B52. DOI: 10.1158/1538-7445.Prca2012-B52 |
0.785 |
|
| 2012 |
Chanda D, Sawant A, Hensel JA, Reilly SD, Siegal GP, Smith C, Isayeva T, Ponnazhagan S. Abstract 5173: The human homologue of frog (Xenopus laevis) anterior gradient protein promotes metastasis via regulation of cellular adhesion Cancer Research. 72: 5173-5173. DOI: 10.1158/1538-7445.Am2012-5173 |
0.793 |
|
| 2012 |
Kumar S, Ponnazhagan S. Bone healing by endogenous stem cell mobilization Bone. 51: 635. DOI: 10.1016/J.Bone.2012.06.011 |
0.35 |
|
| 2011 |
Yang SW, Chanda D, Cody JJ, Rivera AA, Waehler R, Siegal GP, Douglas JT, Ponnazhagan S. Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. Plos One. 6: e25131. PMID 22022379 DOI: 10.1371/Journal.Pone.0025131 |
0.409 |
|
| 2011 |
Triozzi PL, Aldrich W, Ponnazhagan S. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists. Cancer Gene Therapy. 18: 850-8. PMID 21869824 DOI: 10.1038/Cgt.2011.54 |
0.403 |
|
| 2011 |
Yang SW, Cody JJ, Rivera AA, Waehler R, Wang M, Kimball KJ, Alvarez RA, Siegal GP, Douglas JT, Ponnazhagan S. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 538-49. PMID 21115652 DOI: 10.1158/1078-0432.Ccr-10-1628 |
0.382 |
|
| 2011 |
Hensel JA, Chanda D, Kumar S, Sawant A, Grizzle WE, Siegal GP, Ponnazhagan S. LL-37 as a therapeutic target for late stage prostate cancer. The Prostate. 71: 659-70. PMID 20957672 DOI: 10.1002/Pros.21282 |
0.763 |
|
| 2011 |
Chanda D, Sawant A, Isayeva T, Ponnazhagan S. Abstract 5261: Role of anterior gradient protein-2 in prostate cancer bone metastasis Cancer Research. 71: 5261-5261. DOI: 10.1158/1538-7445.Am2011-5261 |
0.487 |
|
| 2011 |
Higgs JT, Jarboe J, Ponnazhagan S. Abstract 3391: Regenerative stem cell therapy for multiple myeloma osteolytic bone damage Cancer Research. 71: 3391-3391. DOI: 10.1158/1538-7445.Am2011-3391 |
0.788 |
|
| 2010 |
Triozzi PL, Aldrich W, Ponnazhagan S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine. 28: 7837-43. PMID 20937315 DOI: 10.1016/J.Vaccine.2010.09.086 |
0.381 |
|
| 2010 |
Lee JH, Moore LD, Kumar S, Pritchard DG, Ponnazhagan S, Deivanayagam C. Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells. Cancer Letters. 298: 238-49. PMID 20688428 DOI: 10.1016/J.Canlet.2010.07.011 |
0.748 |
|
| 2010 |
Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum IE, Siegal GP. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Human Pathology. 41: 1405-12. PMID 20594584 DOI: 10.1016/J.Humpath.2010.02.010 |
0.369 |
|
| 2010 |
Chanda D, Kumar S, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton Journal of Cellular Biochemistry. 111: 249-257. PMID 20506559 DOI: 10.1002/Jcb.22701 |
0.38 |
|
| 2010 |
Kumar S, Wan C, Ramaswamy G, Clemens TL, Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1026-34. PMID 20068549 DOI: 10.1038/Mt.2009.315 |
0.375 |
|
| 2010 |
Kumar S, Nagy TR, Ponnazhagan S. Therapeutic potential of genetically modified adult stem cells for osteopenia Gene Therapy. 17: 105-116. PMID 19741731 DOI: 10.1038/Gt.2009.116 |
0.399 |
|
| 2010 |
Moore LD, Isayeva T, Gurley J, Ponnazhagan S. Abstract 541: TGF-β signaling in the tumor microenvironment promotes tumor formation and tumor progression Cancer Research. 70: 541-541. DOI: 10.1158/1538-7445.Am10-541 |
0.73 |
|
| 2010 |
Chanda D, Sawant A, Isayeva T, Ponnazhagan S. Abstract 231: Mechanism of bone metastasis in prostate cancer: Role of anterior gradient homolog 2 Cancer Research. 70: 231-231. DOI: 10.1158/1538-7445.Am10-231 |
0.511 |
|
| 2010 |
Isayeva T, Chanda D, Tsuladze G, Moore L, Ponnazhagan S. Abstract 1246: Mechanism of endostatin action in prostate cancer in dependent on androgen receptor signaling Cancer Research. 70: 1246-1246. DOI: 10.1158/1538-7445.Am10-1246 |
0.754 |
|
| 2009 |
Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum I, Manne U, Siegal G. Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6027. PMID 27962435 DOI: 10.1200/Jco.2009.27.15_Suppl.6027 |
0.358 |
|
| 2009 |
Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, Beatty MS, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7175-85. PMID 19920103 DOI: 10.1158/1078-0432.Ccr-09-1938 |
0.778 |
|
| 2009 |
Byon CH, Hardy RW, Ren C, Ponnazhagan S, Welch DR, McDonald JM, Chen Y. Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 1221-8. PMID 19752858 DOI: 10.1038/Labinvest.2009.97 |
0.393 |
|
| 2009 |
Westbrook L, Ramanathan HN, Isayeva T, Mittal AR, Qu Z, Johnson MD, Kern FG, Ponnazhagan S, Grubbs CJ, Thottassery JV. High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1. International Journal of Oncology. 34: 1425-31. PMID 19360356 DOI: 10.3892/Ijo_00000271 |
0.427 |
|
| 2009 |
Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. The Prostate. 69: 1055-66. PMID 19301304 DOI: 10.1002/Pros.20952 |
0.737 |
|
| 2008 |
White AF, Mazur M, Sorscher EJ, Zinn KR, Ponnazhagan S. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Human Gene Therapy. 19: 1407-14. PMID 18778196 DOI: 10.1089/Hum.2008.117 |
0.354 |
|
| 2008 |
Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, et al. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4971-80. PMID 18676772 DOI: 10.1158/1078-0432.Ccr-08-0473 |
0.334 |
|
| 2008 |
Moore LD, Isayeva T, Siegal GP, Ponnazhagan S. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4961-70. PMID 18676771 DOI: 10.1158/1078-0432.Ccr-07-4604 |
0.721 |
|
| 2008 |
Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells (Dayton, Ohio). 26: 2332-8. PMID 18617688 DOI: 10.1634/Stemcells.2008-0084 |
0.392 |
|
| 2008 |
Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model Gene Therapy. 15: 1446-1453. PMID 18596829 DOI: 10.1038/Gt.2008.101 |
0.475 |
|
| 2008 |
Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, Reddy VV, Ponnazhagan S. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 871-8. PMID 18388919 DOI: 10.1038/Mt.2008.48 |
0.47 |
|
| 2008 |
Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Therapy. 15: 711-5. PMID 18356815 DOI: 10.1038/Gt.2008.35 |
0.377 |
|
| 2008 |
Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Bryant CS, Kumar S, Prasad M, Ponnazhagan S, Chanda D, Steffes CP, Munshi NC, De Vivo I, Beer DG, et al. W1953 Effect of a Novel Telomerase Inhibitor, Grn163l, On Growth of Barrett's Esophageal Adenocarcinoma Cells In Vitro and In Vivo Gastroenterology. 134: A-741. DOI: 10.1016/S0016-5085(08)63460-5 |
0.315 |
|
| 2007 |
Kumar S, Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 3917-27. PMID 17622670 DOI: 10.1096/Fj.07-8275Com |
0.411 |
|
| 2007 |
Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Research. 67: 5789-97. PMID 17575146 DOI: 10.1158/0008-5472.Can-06-3637 |
0.467 |
|
| 2007 |
Pereboeva L, Komarova S, Roth J, Ponnazhagan S, Curiel DT. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus Gene Therapy. 14: 627-637. PMID 17251987 DOI: 10.1038/Sj.Gt.3302916 |
0.302 |
|
| 2007 |
Ren C, White AF, Ponnazhagan S. Notch1 augments intracellular trafficking of adeno-associated virus type 2. Journal of Virology. 81: 2069-73. PMID 17151095 DOI: 10.1128/Jvi.01811-06 |
0.419 |
|
| 2006 |
White AF, Ponnazhagan S. Airway epithelium directed gene therapy for cystic fibrosis. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 2: 499-503. PMID 17017989 DOI: 10.2174/157340606778250180 |
0.327 |
|
| 2006 |
Isayeva T, Ren C, Ponnazhagan S. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Therapy. 14: 138-46. PMID 16943851 DOI: 10.1038/Sj.Gt.3302853 |
0.396 |
|
| 2006 |
Sorscher EJ, Harris J, Alexander M, Rottgers A, Hardy K, Ponnazhagan S, Collawn JF, McClintock J, Amsler CD, Webster A, Maddry J, Baker BJ, Hong JS. Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. Gene Therapy. 13: 781-8. PMID 16307002 DOI: 10.1038/Sj.Gt.3302676 |
0.344 |
|
| 2006 |
Kumar S, Nagy TR, Ponnazhagan S. 568. Ex Vivo Mesenchymal Stem Cell Therapy with rAAV2 Encoding BMP-2 Enhances Bone Regeneration in Ovariectomized Mouse Model Molecular Therapy. 13: S219. DOI: 10.1016/J.Ymthe.2006.08.641 |
0.403 |
|
| 2006 |
Isayeva T, Chanda D, Ponnazhagan S. 295. Effects of Sustained Anti-Angiogenic Gene Therapy in Multi-Stage Prostate Cancer in TRAMP Mice Molecular Therapy. 13: S112. DOI: 10.1016/J.Ymthe.2006.08.350 |
0.475 |
|
| 2006 |
Ren C, White AF, Ponnazhagan S. 4. Role of Notch1 in Augmenting Intracellular Trafficking and Transgene Expression of Recombinant Adeno-Associated Virus-2 Molecular Therapy. 13: S2. DOI: 10.1016/J.Ymthe.2006.08.014 |
0.421 |
|
| 2005 |
Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Research. 65: 10041-9. PMID 16267030 DOI: 10.1158/0008-5472.Can-05-1383 |
0.326 |
|
| 2005 |
Kumar S, Mahendra G, Ponnazhagan S. Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction. Biochimica Et Biophysica Acta. 1731: 95-103. PMID 16225939 DOI: 10.1016/J.Bbaexp.2005.08.007 |
0.358 |
|
| 2005 |
Ren C, Kumar S, Shaw DR, Ponnazhagan S. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo. Human Gene Therapy. 16: 1047-57. PMID 16149903 DOI: 10.1089/Hum.2005.16.1047 |
0.315 |
|
| 2005 |
Mahendra G, Kumar S, Isayeva T, Mahasreshti PJ, Curiel DT, Stockardt CR, Grizzle WE, Alapati V, Singh R, Siegal GP, Meleth S, Ponnazhagan S. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Therapy. 12: 26-34. PMID 15359287 DOI: 10.1038/Sj.Cgt.7700754 |
0.449 |
|
| 2005 |
Aldrich WA, Ren C, White A, Zhou S, Kumar S, Jenkins CB, Shaw DR, Strong TV, Triozzi PL, Ponnazhagan S. 849. Transduction of Mouse Dendritic Cells Is Enhanced by Repetitive Infection with Self-Complementary Adeno-Associated Virus 6 Combined with Immunostimulatory Ligands Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.392 |
0.371 |
|
| 2005 |
White AF, Mazur M, Sorscher EJ, Ponnazhagan S. 507. Modeling Adeno-Associated Virus 2 Capsid for the Identification of Targeting Ligands for Enhanced Gene Transfer to Polarized Human Airway Epithelial Cells Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.047 |
0.354 |
|
| 2005 |
Kumar S, Ponnazhagan S. 136. Recombinant Adeno-Associated Virus 2-Mediated Ectopic Expression of |[alpha]|4|[beta]|1 Integrin in Mouse Mesenchymal Stem Cells Enhances Repopulation to Bone upon Syngeneic Transplantation in an Immunocompetent Mouse Model Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.141 |
0.424 |
|
| 2005 |
Isayeva T, Ren C, Ponnazhagan S. 119. Intraperitoneal Transduction of Adeno-Associated Virus 2 Expressing Angiostatin and Endostatin Synergistically Augments Paclitaxel Therapy and Tumor-Free Survival in a Mouse Model of Epithelial Ovarian Cancer Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.124 |
0.447 |
|
| 2004 |
Chaudhuri TR, Cao Z, Ponnazhagan S, Stargel A, Simhadri PL, Zhou T, Lobuglio AF, Buchsbaum DJ, Zinn KR. Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 742. PMID 28013631 DOI: 10.1200/Jco.2004.22.14_Suppl.742 |
0.372 |
|
| 2004 |
Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Human Gene Therapy. 15: 1197-206. PMID 15684696 DOI: 10.1089/Hum.2004.15.1197 |
0.418 |
|
| 2004 |
Kumar S, Ponnazhagan S. Gene therapy for osteoinduction. Current Gene Therapy. 4: 287-96. PMID 15384942 DOI: 10.2174/1566523043346219 |
0.383 |
|
| 2004 |
Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Human Gene Therapy. 15: 856-64. PMID 15353040 DOI: 10.1089/Hum.2004.15.856 |
0.409 |
|
| 2004 |
Isayeva T, Kumar S, Ponnazhagan S. Anti-angiogenic gene therapy for cancer (review). International Journal of Oncology. 25: 335-43. PMID 15254730 |
0.304 |
|
| 2004 |
Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Research. 64: 1781-7. PMID 14996740 DOI: 10.1158/0008-5472.Can-03-1786 |
0.434 |
|
| 2004 |
Ponnazhagan S, Hoover F. Delivery of DNA to tumor cells in vivo using adeno-associated virus. Methods in Molecular Biology (Clifton, N.J.). 246: 237-43. PMID 14970597 DOI: 10.1385/1-59259-650-9:237 |
0.435 |
|
| 2004 |
Ponnazhagan S. Parvovirus vectors for cancer gene therapy. Expert Opinion On Biological Therapy. 4: 53-64. PMID 14680468 DOI: 10.1517/14712598.4.1.53 |
0.388 |
|
| 2004 |
Isayeva T, Kumar S, Ponnazhagan S. Anti-angiogenic gene therapy for cancer (review). International Journal of Oncology. 25: 335-343. DOI: 10.3892/Ijo.25.2.335 |
0.418 |
|
| 2004 |
Kumar S, Mahendra G, Ponnazhagan S. 886. Determination of Osteoprogenitor-Specific Promoter Activity in Murine Mesenchymal Stem Cells by Recombinant Adeno-Associated Virus Transduction Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.792 |
0.423 |
|
| 2004 |
Ren C, Kumar S, Ponnazhagan S. 746. Genomic Stability of Self-Complementary Recombinant Adeno-Associated Virus 2 in Mouse Muscle Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.668 |
0.302 |
|
| 2004 |
Ponnazhagan S, Mahendra G, Lima J, Aldrich W, Jenkins C, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. 619. Augmentation of Anti-Tumor Activity of a Recombinant Adeno-Associated Virus 2 Carcinoembryonic Antigen Vaccine with Plasmid Adjuvants Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.543 |
0.423 |
|
| 2004 |
Isayeva T, Ren C, Ponnazhagan S. 434. Recombinant Adeno-Associated Virus 2 -Mediated Anti-Angiogenic Gene Therapy in a Mouse Model of Intraperitoneal Ovarian Cancer Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.400 |
0.44 |
|
| 2002 |
Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. Journal of Virology. 76: 12900-7. PMID 12438615 DOI: 10.1128/Jvi.76.24.12900-12907.2002 |
0.358 |
|
| 2001 |
Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo immunotherapy Journal of Virology. 75: 9493-9501. PMID 11533211 DOI: 10.1128/Jvi.75.19.9493-9501.2001 |
0.353 |
|
| 1999 |
Kurpad C, Mukherjee P, Wang XUS, Ponnazhagan S, Li L, Yoder MC, Srivastava A. Adeno-associated virus 2-mediated transduction and erythroid lineage- restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells Journal of Hematotherapy and Stem Cell Research. 8: 585-592. PMID 10645765 DOI: 10.1089/152581699319740 |
0.387 |
|
| 1998 |
Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, Kube DM, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression Journal of Virology. 72: 9835-9843. PMID 9811719 DOI: 10.1128/Jvi.72.12.9835-9843.1998 |
0.355 |
|
| 1998 |
Ponnazhagan S, Weigel KA, Raikwar SP, Mukherjee P, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: Erythroid cell-specific delivery and expression of transduced genes Journal of Virology. 72: 5224-5230. PMID 9573295 DOI: 10.1128/Jvi.72.6.5224-5230.1998 |
0.373 |
|
| 1998 |
Qing K, Khuntirat B, Mah C, Kube DM, Wang XS, Ponnazhagan S, Zhou S, Dwarki VJ, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. Journal of Virology. 72: 1593-9. PMID 9445062 DOI: 10.1128/Jvi.72.2.1593-1599.1998 |
0.381 |
|
| 1997 |
Ponnazhagan S, Mukherjee P, Wang XS, Qing K, Kube DM, Mah C, Kurpad C, Yoder MC, Srour EF, Srivastava A. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. Journal of Virology. 71: 8262-7. PMID 9343178 DOI: 10.1128/Jvi.71.11.8262-8267.1997 |
0.402 |
|
| 1997 |
Ponnazhagan S, Mukherjee P, Yoder MC, Wang XS, Zhou SZ, Kaplan J, Wadsworth S, Srivastava A. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene. 190: 203-10. PMID 9185868 DOI: 10.1016/S0378-1119(96)00576-8 |
0.357 |
|
| 1997 |
Ponnazhagan S, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo Journal of Virology. 71: 3098-3104. PMID 9060672 DOI: 10.1128/Jvi.71.4.3098-3104.1997 |
0.405 |
|
| 1997 |
Ponnazhagan S, Erikson D, Kearns WG, Zhou SZ, Nahreini P, Wang XS, Srivastava A. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Human Gene Therapy. 8: 275-84. PMID 9048194 DOI: 10.1089/Hum.1997.8.3-275 |
0.304 |
|
| 1997 |
Kube DM, Ponnazhagan S, Srivastava A. Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells. Journal of Virology. 71: 7361-7371. DOI: 10.1128/Jvi.71.10.7361-7371.1997 |
0.363 |
|
| 1996 |
Srivastava A, Wang XS, Ponnazhagan S, Zhou SZ, Yoder MC. Adeno-associated virus 2-mediated transduction and erythroid lineage-specific expression in human hematopoietic progenitor cells Current Topics in Microbiology and Immunology. 218: 93-117. PMID 8794248 DOI: 10.1007/978-3-642-80207-2_7 |
0.313 |
|
| 1996 |
Ponnazhagan S, Wang XS, Woody MJ, Luo F, Kang LY, Nallari ML, Munshi NC, Zhou SZ, Srivastava A. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. The Journal of General Virology. 77: 1111-22. PMID 8683195 DOI: 10.1099/0022-1317-77-6-1111 |
0.363 |
|
| 1996 |
Broxmeyer HE, Cooper S, Etienne-Julan M, Wang XS, Ponnazhagan S, Braun S, Lu L, Srivastava A. Cord blood transplantation and the potential for gene therapy. Gene transduction using a recombinant adeno-associated viral vector. Annals of the New York Academy of Sciences. 770: 105-15. PMID 8597353 DOI: 10.1111/J.1749-6632.1995.Tb31048.X |
0.328 |
|
| 1995 |
Ponnazhagan S, Woody MJ, Wang XS, Zhou SZ, Srivastava A. Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. Journal of Virology. 69: 8096-101. PMID 7494329 DOI: 10.1128/Jvi.69.12.8096-8101.1995 |
0.34 |
|
| 1994 |
Ponnazhagan S, Hou L, Kwon BS. Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. The Journal of Investigative Dermatology. 102: 744-8. PMID 8176257 DOI: 10.1111/1523-1747.Ep12376924 |
0.308 |
|
| 1992 |
Ponnazhagan S, Kwon BS. A cis-acting element involved in mouse tyrosinase gene expression and partial purification of its binding protein Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 5: 155-161. PMID 1494537 DOI: 10.1111/J.1600-0749.1992.Tb00453.X |
0.358 |
|
| Show low-probability matches. |